Top ten highlights from the APAC PE, VC, and startup ecosystem this week:
- Exit Deal Value Plummeted: Bain report shows exit deal value in Southeast Asia dropped by 60% to $2.8 billion in 2023, leading to a 70% decrease in the number of exits compared to the previous year.
- Tower Capital Asia’s Bullish Exit: Tower Capital Asia achieved a successful exit with Chinese medicine retailer Eu Yan Sang International, yielding an IRR in the top quartile.
- Southern Capital Group’s Sale: Southern Capital Group finalized the sale of the Australian subsidiary of Qualitas Medical Health Group, showcasing ongoing activity in the healthcare sector.
- Apis Partners’ Exit: London-based Apis Partners sold its stake in Southeast Asian payments provider GHL Systems Berhad to Japanese tech firm NTT DATA, marking its eighth exit.
- Growing Interest in Southeast Asia: Limited partners are showing increased interest in Southeast Asia due to its established market, diverse economies, and favorable corporate history.
- Malaysia’s PE Commitments: Malaysia’s public service retirement fund KWAP committed RM6 billion to its private equity strategy, while Ekuinas plans to launch a private credit fund.
- IFC’s Investment: International Finance Corporation is considering a $40 million investment in Actis’ new private equity fund focusing on climate transition in Asia.
- Taiwan’s Capital Commitments: Fubon Life Insurance and Cathay Life Insurance made $130 million in new capital commitments to private equity funds.
- China’s Semiconductor Fund: China established its third state-backed investment fund to boost the semiconductor industry with a registered capital of 344 billion yuan.
- Fundraising Success: EQT Private Capital Asia closed its mid-market fund at $1.6 billion, surpassing its initial target, while Seraya Partners plans to raise its second fund in the near future.
Disclaimer:This article by is general in nature and based on publicly available information and not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material. While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
